OS Therapies Reports Strong 2-Year Survival Data For Bone Cancer Immunotherapy Candidate

benzinga.com/news/health-care/25/10/48149412/os-therapies-reports-strong-2-year-survival-data-for-bone-cancer-immunotherapy-candidate

OS Therapies Inc. (NYSE:OSTX), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, released survival data on Friday from the Phase 2b trial of its off-the-shelf immunotherapy candidate, OST-HER2, for pulmonary metastatic osteosarcoma, an aggressive…

This story appeared on benzinga.com, 2025-10-10 14:40:05.
The Entire Business World on a Single Page. Free to Use →